开源证券给予天士力买入评级，优化研发布局提升竞争力

Group 1 - The core viewpoint of the report is that Tian Shi Li (600535.SH) is given a "buy" rating due to its strong profit growth and effective cost control [2] - The pharmaceutical industrial segment experienced a slight revenue decline, but sales of products across multiple fields are showing positive trends [2] - The company is enhancing its competitiveness through innovative strategies centered around the "disease tree" and "product tree," optimizing its research and development layout [2]